Editor's letter

Welcome to the latest issue of Pharmaceutical Technology Focus magazine

Artificial intelligence (AI) has found a regular place in clinical trials, from recruitment to anaysis - but are the regulators keeping up?

This month's cover feature examines the realities of the technology appearing far ahead of regulation, and examines what the regulators are planning in response.

Also in this issue, we examined what newborn screening protocols may emerge in the US since the disbandment of the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC), a federally appointed body under the US Health Resources and Services Administration (HRSA), in April. Don’t miss our analyst comments on several intiguing poster session from the 2025 American Thoracic Society (ATS) International Conference.

All this and the latest pharma industry news, comment, and analysis from GlobalData.

Ross Law, deputy editor